{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:27:22Z","timestamp":1786944442560,"version":"build-2736575974"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academic Clinical Lectureship","award":["CL-2024-14-001"],"award-info":[{"award-number":["CL-2024-14-001"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biology to Prevention Award","award":["PRCBTP-May25\/100019"],"award-info":[{"award-number":["PRCBTP-May25\/100019"]}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["SGL032\\1079"],"award-info":[{"award-number":["SGL032\\1079"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>KRAS mutations are common in colorectal cancer, but the impact of KRAS mutation subtypes on treatment response remains poorly understood. This research aimed to investigate whether different KRAS mutations influence pathological complete response (pCR) rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer (LARC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of studies describing genetic determinants of response to neoadjuvant chemoradiotherapy in LARC was conducted, searching for manuscripts published up to March 2026. The primary outcome of interest was the odds ratio for KRAS mutations and pCR. A random-effects model estimated the pooled effect size of KRAS mutations within and outside exon 2 on pCR. Genomic data sets were analysed to investigate the molecular characteristics of KRAS exon 2 and non-exon 2 mutant rectal cancers and their impact on overall and disease-free survival. Finally, a transcriptomic data set was analysed to elucidate the underlying response mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 11 537 manuscripts identified, 15 studies (3354 patients) were included in the meta-analysis. The odds ratio for any KRAS mutation and pCR was 0.48 (95% confidence interval 0.32 to 0.70), indicating reduced odds of pCR in KRAS-mutant LARC. Subgroup analysis revealed that KRAS mutations in exon 2 accounted for this effect, whereas variants outside exon 2 had no influence (odds ratio 0.96, 95% confidence interval 0.11 to 8.49). Analysis confirmed poorer disease-free survival in patients with exon 2 alterations (P = 0.019) as well as poorer overall survival (P = 0.047). Transcriptomic analysis revealed that non-exon 2 KRAS-mutant tumours were enriched for inflammatory signalling pathways, suggesting that these tumours represent a subgroup with high immune infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The presence of KRAS mutations adversely affects pCR odds after neoadjuvant chemoradiotherapy in LARC, but this effect is specific to exon 2 mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjsopen\/zrag080","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T11:32:57Z","timestamp":1779017577000},"source":"Crossref","is-referenced-by-count":0,"title":["Influence of\n                    <i>KRAS<\/i>\n                    mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-1252","authenticated-orcid":false,"given":"Iannish D","family":"Sadien","sequence":"first","affiliation":[{"name":"Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way , Cambridge ,","place":["UK"]},{"name":"Cambridge Colorectal Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]},{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Cooper","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Cambridge Medical Library, University of Cambridge School of Clinical Medicine , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heman","family":"Joshi","sequence":"additional","affiliation":[{"name":"Cambridge Colorectal Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Cambridge Colorectal Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Justin","family":"Davies","sequence":"additional","affiliation":[{"name":"Cambridge Colorectal Unit, Cambridge University Hospitals NHS Foundation Trust , Cambridge ,","place":["UK"]},{"name":"School of Clinical Medicine, University of Cambridge , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026081701214696000_zrag080-B1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"2026081701214696000_zrag080-B2","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081701214696000_zrag080-B3","first-page":"288","article-title":"The evolving field of neoadjuvant therapy in locally-advanced rectal cancer: evidence and prospects","volume":"20","author":"Ominelli","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"2026081701214696000_zrag080-B4","doi-asserted-by":"crossref","first-page":"103927","DOI":"10.1016\/j.critrevonc.2023.103927","article-title":"A systematic review and network meta-analysis of randomised controlled trials comparing neoadjuvant treatment strategies for stage II and III rectal cancer","volume":"183","author":"Simillis","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026081701214696000_zrag080-B5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026081701214696000_zrag080-B6","doi-asserted-by":"crossref","first-page":"zrae038","DOI":"10.1093\/bjsopen\/zrae038","article-title":"Neoadjuvant treatment of colorectal cancer: comprehensive review","volume":"8","author":"Smith","year":"2024","journal-title":"BJS Open"},{"key":"2026081701214696000_zrag080-B7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2026081701214696000_zrag080-B8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2026081701214696000_zrag080-B9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/mco.2016.836","article-title":"Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: a meta-analysis","volume":"4","author":"Lin","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"2026081701214696000_zrag080-B10","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/cancers15051469","article-title":"Predictive and prognostic value of oncogene mutations and microsatellite instability in locally-advanced rectal cancer treated with neoadjuvant radiation-based therapy: a systematic review and meta-analysis","volume":"15","author":"De Mattia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026081701214696000_zrag080-B11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suronc.2013.02.001","article-title":"KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis","volume":"22","author":"Clancy","year":"2013","journal-title":"Surg Oncol"},{"key":"2026081701214696000_zrag080-B12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00384-021-03911-z","article-title":"KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis","volume":"36","author":"Peng","year":"2021","journal-title":"Int J Colorectal Dis"},{"key":"2026081701214696000_zrag080-B13","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026081701214696000_zrag080-B14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41586-025-08931-1","article-title":"Targeting the SHOC2\u2013RAS interaction in RAS-mutant cancers","volume":"642","author":"Hauseman","year":"2025","journal-title":"Nature"},{"key":"2026081701214696000_zrag080-B15","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1245\/s10434-013-2910-0","article-title":"Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma","volume":"20","author":"Duldulao","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2026081701214696000_zrag080-B16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026081701214696000_zrag080-B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026081701214696000_zrag080-B18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"2026081701214696000_zrag080-B19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"2026081701214696000_zrag080-B20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026081701214696000_zrag080-B21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/2767-9764.CRC-23-0502","article-title":"Stratification to neoadjuvant radiotherapy in rectal cancer by regimen and transcriptional signatures","volume":"4","author":"Mahmood","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026081701214696000_zrag080-B22","author":"Kassambara"},{"key":"2026081701214696000_zrag080-B23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2026081701214696000_zrag080-B24","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","article-title":"Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer","volume":"28","author":"Chatila","year":"2022","journal-title":"Nat Med"},{"key":"2026081701214696000_zrag080-B25","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026081701214696000_zrag080-B26","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1093\/nar\/gks461","article-title":"Camera: a competitive gene set test accounting for inter-gene correlation","volume":"40","author":"Wu","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2026081701214696000_zrag080-B27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2026081701214696000_zrag080-B28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.21873\/anticanres.16362","article-title":"Prognostic impact of Ras mutation on surgical strategy in rectal cancer patients undergoing neoadjuvant treatment","volume":"43","author":"Orlandi","year":"2023","journal-title":"Anticancer Res"},{"key":"2026081701214696000_zrag080-B29","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0b013e31822b8cfa","article-title":"Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer","volume":"254","author":"Garcia-Aguilar","year":"2011","journal-title":"Ann Surg"},{"key":"2026081701214696000_zrag080-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8459303","article-title":"Analysis of molecular pretreated tumor profiles as predictive biomarkers of therapeutic response and survival outcomes after neoadjuvant therapy for rectal cancer in Moroccan population","volume":"2020","author":"El Otmani","year":"2020","journal-title":"Dis Markers"},{"key":"2026081701214696000_zrag080-B31","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jamcollsurg.2011.02.024","article-title":"Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer","volume":"212","author":"Chen","year":"2011","journal-title":"J Am Coll Surg"},{"key":"2026081701214696000_zrag080-B32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/DCR.0000000000002245","article-title":"Rectal cancer: clinical and molecular predictors of a complete response to total neoadjuvant therapy","volume":"66","author":"Chapman","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"2026081701214696000_zrag080-B33","first-page":"102","article-title":"Tumor heterogeneity as a predictor of response to neoadjuvant chemotherapy in locally advanced rectal cancer","volume":"18","author":"Greenbaum","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"2026081701214696000_zrag080-B34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1748-717X-6-114","article-title":"Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy","volume":"6","author":"Davies","year":"2011","journal-title":"Radiation Oncology"},{"key":"2026081701214696000_zrag080-B35","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.3390\/ijms231810353","article-title":"Targeted next-generation sequencing-based multiple gene mutation profiling of patients with rectal adenocarcinoma receiving or not receiving neoadjuvant chemoradiotherapy","volume":"23","author":"Chang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026081701214696000_zrag080-B36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12029-013-9546-y","article-title":"Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer","volume":"45","author":"Russo","year":"2014","journal-title":"J Gastrointest Cancer"},{"key":"2026081701214696000_zrag080-B37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjc.6605853","article-title":"Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy","volume":"103","author":"Bengala","year":"2010","journal-title":"Br J Cancer"},{"key":"2026081701214696000_zrag080-B38","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1007\/s11033-020-05973-8","article-title":"The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study","volume":"47","author":"Bahnassy","year":"2020","journal-title":"Mol Biol Rep"},{"key":"2026081701214696000_zrag080-B39","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3390\/cancers12071808","article-title":"Genomic and transcriptomic characterisation of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer","volume":"12","author":"Toomey","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026081701214696000_zrag080-B40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-019-02576-y","article-title":"Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer","volume":"475","author":"Jiang","year":"2019","journal-title":"Virchows Archiv"},{"key":"2026081701214696000_zrag080-B41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13304-015-0281-8","article-title":"Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer","volume":"67","author":"Martellucci","year":"2015","journal-title":"Updates Surg"},{"key":"2026081701214696000_zrag080-B42","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1245\/s10434-016-5205-4","article-title":"KRAS and combined KRAS\/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy","volume":"23","author":"Chow","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2026081701214696000_zrag080-B43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jso.26244","article-title":"Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer","volume":"123","author":"Zhou","year":"2021","journal-title":"J Surg Oncol"},{"key":"2026081701214696000_zrag080-B44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.34880","article-title":"Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer","volume":"155","author":"Hammarstr\u00f6m","year":"2024","journal-title":"Int J Cancer"},{"key":"2026081701214696000_zrag080-B45","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"2026081701214696000_zrag080-B46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00066-023-02097-3","article-title":"Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review","volume":"199","author":"Becherini","year":"2023","journal-title":"Strahlentherapie und Onkologie"},{"key":"2026081701214696000_zrag080-B47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2026081701214696000_zrag080-B48","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"2026081701214696000_zrag080-B49","doi-asserted-by":"crossref","first-page":"m461","DOI":"10.1136\/bmj.m461","article-title":"Colorectal cancer: summary of NICE guidance","volume":"368","author":"Bromham","year":"2020","journal-title":"BMJ"},{"key":"2026081701214696000_zrag080-B50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026081701214696000_zrag080-B51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.15252\/embr.201439949","article-title":"Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure","volume":"16","author":"Pagliarini","year":"2015","journal-title":"EMBO Rep"},{"key":"2026081701214696000_zrag080-B52","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/bjs\/znad177","article-title":"Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials","volume":"110","author":"Donnelly","year":"2023","journal-title":"Br J Surg"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/4\/zrag080\/70482810\/zrag080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/10\/4\/zrag080\/70482810\/zrag080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:22:02Z","timestamp":1786944122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrag080\/8751281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrag080","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,3]]},"article-number":"zrag080"}}